METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT PATIENTS SUFFERING FROM MYELOPROLIFERATIVE DISORDERS
The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a dysregulation of the JAK2-STAT signalling pathway. Using MPN mouse model and clonogenic methyl-cellulose cultures of patient progenitors, the inventors demonstrate that combining ARS with IFN improves most of the benefits provided by IFN alone during MPN treatment. In particular, the present invention relates to a method of treating a myeloproliferative disorder in a patient presenting a dysregulation of the JAK2-STAT signalling pathway comprising administering to the patient a therapeutically effective combination of an interferon polypeptide and an arsenic compound.
1 . A method of treating a myeloproliferative disorder in a patient presenting a dysregulation of the JAK2-STAT signalling pathway comprising administering to the patient a therapeutically effective combination of an interferon polypeptide and an arsenic compound.
2 . The method of claim 1 wherein the patient suffers from a myeloproliferative neoplasm (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET) or primary myelofibrosis (PMF).
3 . The method of claim 1 wherein the patient suffers from a myelodysplastic syndrome.
4 . The method of claim 1 wherein the patient harbors at least one mutation in JAK2, MPL, or CALR.
5 . The method of claim 4 wherein the JAK2 mutation is JAK2V617F mutation.
6 . The method of claim 4 wherein the JAK 2 mutation is selected from the group consisting of N542-E543del, K537L, E543-D544del and F537-K39delinsL and R541-E543delinsK.
7 . The method of claim 4 wherein the MPL mutation is selected from the group consisting of MPLS505N; MPLW515L, MPLW515K, MPLW515A, PMLW515R and MPLW515S.
8 . The method of claim 4 wherein the MPL mutation is selected from the group consisting of V501A, S505C, A506T, V507I, G509C, L510P, R514K and R519T.
9 . The method of claim 4 wherein the CALR mutation is selected from the group consisting of CALRde152/type I; c.1092_1143del; L367 fs*46 and c1154_1155insTTGTC; K385 fs*47
10 . The method of claim 1 wherein the interferon polypeptide is an interferon-alpha (IFN-a) polypeptide.
11 . The method of claim 10 wherein the interferon-alpha is pegylated.
12 . The method of claim 1 wherein the arsenic compound is selected from the group consisting of arsenic, arsenic trioxide (As2O3), melarsoprol and arsenic sulfur derivative.